March 23, 2017 | China, Events, Patient journey, Pei Li Teh, Pharma China Annual Forum, emerging markets
We are delighted to be presenting a paper at the Pharma China Annual Forum on 14th April 2017 in Shanghai, China.
Representing Research Partnership will be Asia Pacific Director and emerging markets specialist Pei Li Teh, who will be presenting the paper ’Urban China’s Evolving Patient Journey’ from 14:30 – 15:00.Â
The patient is an important stakeholder in the treatment of chronic conditions in urban China. Patients, as well as their family members, play an important role in determining their own treatment. They decide when to present, they choose the hospital, many pay out of their own pocket for treatments and they are perhaps the key determinant in the duration of therapy. Therefore it is essential  to understand how the patient journey is evolving and the extent to which this will impact the pharmaceutical industry in the next 5 years.Â
This paper will outline the universal truths of the chronic disease patient journey in China, as well as the key inflection points that have the biggest impact on treatment outcomes. Finally, by exploring the distinct healthcare challenges that China looks set to face, Pei Li will discuss the potential for pharma to address these challenges using a series of detailed case studies.Â
Throughout the event Pei Li will be on hand to answer any questions you might have regarding our expertise and experience in emerging markets. If you are planning to attend the Pharma China Annual Forum and would like to meet with Pei Li, or are unable to attend but would be interested in receiving a copy of the paper please feel free to contact us.
Research Partnership is committed to staying at the cutting edge of healthcare research in emerging markets. As well as attending relevant conferences and exhibitions we are also regular speakers at relevant forums.
Find out more:Â http://bit.ly/2mXl6PY
This content was provided by Inizio
Latest Content from Inizio
As the oncology landscape continues to evolve, life sciences organizations face a growing challenge: how do you communicate increasingly complex science in a way that creates meaningful engagement?
Pharma teams are under growing pressure to navigate launch complexity, identify risks earlier, and engage HCPs more effectively.
This guidebook explores how Intelligent Congress helps pharma teams create more coordinated, measurable, and impactful congress strategies.
Commercial pharma launches depend on confident, evidence-led decisions. Yet many launch teams are still working with fragmented data spread across multiple systems, making it difficult to understand market readiness, prioritize…
Following ASCO® 2026, Inizio’s experts have shared their perspectives across three thought leadership articles, each exploring a different aspect of what this year’s congress revealed for pharmaceutical organisations. Together, they…
Key insights from ASCO® 2026, including oncology trends, scientific highlights, and strategies for smarter congress engagement.
Across sessions, panels, and conversations on the ground in Denver, there was a noticeable shift in both mindset and momentum. Many of the themes discussed in previous years are now…
Inizio, the global commercialization partner to the health and life sciences industry, today announced the launch of Intelligent Congress – a connected, end-to-end solution designed to help pharma organizations maximize…
Integrated capabilities combining advanced analytics, pharmacy, and specialized talent to improve access, affordability, and adherence
Pharma USA is North America’s largest cross-functional pharma event and Inizio was there to offer insights on patient engagement, accelerated product launches, and Intelligent Commercializationâ„¢. Now we’re back in the…
